As of mid-2022, when considering antiviral therapy for a child with chronic hepatitis C, the main available options are: a combination of sofosbuvir (an inhibitor of the NS5B RNA polymerase of HCV) + velpatasvir (an inhibitor of the HCV NS5A protein), authorised from 6 years of age; and combinations of sofosbuvir + ribavirin (a nucleoside analogue) and sofosbuvir+ledipasvir (an NS5A protein inhibitor), authorised from 3 years of age. These treatments have similar antiviral efficacy, producing a "sustained virologic response" in more than 90% of children in the trials. The choice from among these combinations mainly depends on the virus genotype.
展开▼
